Gene expression profiling in multiple myeloma - Reporting of entities, risk, and targets in clinical routine

Clinical Cancer Research

Volumn 17, Issue 23, 2011, Pages 7240-7247

  Meißner, Tobias ^a,b   Seckinger, Anja ^a,b   Rème, Thierry ^d,e,f   Hielscher, Thomas ^c   Möhler, Thomas ^a   Neben, Kai ^a   Goldschmidt, Hartmut ^a,b   Klein, Bernard ^d,e,f   Hose, Dirk ^a,b  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b Nationales Centrum fur Tumorerkrankungen   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d INSERM   (France)

^e MONTPELLIER UNIVERSITY HOSPITAL   (France)

^f UNIV MONTPELLIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIOLOGICAL TRAIT; CANCER RISK; CLINICAL ASSESSMENT TOOL; CLINICAL PRACTICE; COMPUTER ANALYSIS; COMPUTER PROGRAM; CONTROLLED STUDY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE TARGETING; HUMAN; INFORMATION PROCESSING; MICROARRAY ANALYSIS; MOLECULAR PATHOLOGY; MULTIPLE MYELOMA; NUCLEOTIDE SEQUENCE; PATIENT CODING; PRIORITY JOURNAL; PROGNOSIS; QUALITY CONTROL; RISK ASSESSMENT; SAMPLE; SURVIVAL RATE;

ALGORITHMS; CHROMOSOME ABERRATIONS; DATA INTERPRETATION, STATISTICAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICROARRAY ANALYSIS; MULTIPLE MYELOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; SOFTWARE;

EID: 82555194601     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1628     Document Type: Article

References (50)

1. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004;351:1860-73.
2. Hose D, Moreaux J, Meissner T, Seckinger A, Goldschmidt H, Benner A, et al. Induction of angiogenesis by normal and malignant plasma cells. Blood 2009;114:128-43.
3. Hose D, Rème T, Meissner T, Moreaux J, Seckinger A, Lewis J, et al. Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma. Blood 2009;113:4331-40.
4. Seckinger A, Meissner T, Moreaux J, Goldschmidt H, Fuhler GM, Benner A, et al. Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis. Oncogene 2009;28:3866-79.
5. Sprynski AC, Hose D, Caillot L, Reme T, Shaughnessy JD Jr, Barlogie B, et al. The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor. Blood 2009;113:4614-26.
6. Barlogie B, Anaissie EJ, van Rhee F, Shaughnessy JD, Haessler J, Pineda-Roman M, et al. Total therapy (TT) for myeloma (MM)-10% cure rate with TT1 suggested by >10yr continuous complete remission (CCR): bortezomib in TT3 overcomes poor-risk associated with T(4;14) and DelTP53 in TT2. J Clin Oncol 26, 2008 (May 20 suppl; abstr 8516).
7. Barlogie B, Tricot GJ, van Rhee F, Angtuaco E, Walker R, Epstein J, et al. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol 2006;135:158-64. (Pubitemid 44401612)
8. Harousseau JL, Moreau P. Autologous hematopoietic stem-cell transplantation for multiple myeloma. N Engl J Med 2009;360:2645-54.
9. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, et al. The molecular classification of multiple myeloma. Blood 2006;108:2020-8. (Pubitemid 44395016)
10. Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 2005;23:6333-8. (Pubitemid 46218843)
11. Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 2005;106:296-303. (Pubitemid 40967205)
12. Hose D, Rossi J-Fo, Ittrich C, DeVos J, RŠme T, Benner A, et al. Molecular classification of multiple myeloma (MM) based on gene expression profiling (GEP) and fluorescence in situ hybridisation (FISH) is an independent predictor for event free survival (EFS). [abstract]. Blood 2005;106:150a-a.
13. Hose D, Rossi J-F, Ittrich C, de Vos J, Reme T, Benner A, et al. A new molecular classification of multiple myeloma (MM) using gene expression profiling (GEP) and fluorescence in situ hybridisation as predictor for event free survival (EFS). [abstract]. Blood 2004;104:25a-a.
14. Shaughnessy JD, Zhan F, Burington BE, Huang Y, Colla S,Hanamura I, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007;109:2276-84. (Pubitemid 46425864)
15. Decaux O, Lodé L, Magrangeas F, Charbonnel C, Gouraud W, Jézéquel P, et al. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome. J Clin Oncol 2008;26:4798-805.
16. Hose D, Reme T, Hielscher T, Moreaux J, Messner T, Seckinger A, et al. Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma. Haematologica 2011;96:87-95.
17. Trudel S, Li ZH, Wei E, Wiesmann M, Chang H, Chen C, et al. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood 2005;105:2941-8. (Pubitemid 40446289)
18. Condomines M, Hose D, Raynaud P, Hundemer M, Vos JD, Baudard M, et al. Cancer/testis genes in multiplemyeloma: expression patterns and prognosis value determined by microarray analysis. J Immunol 2007;178:3307-15. (Pubitemid 46333216)
19. Szmania S, Gnjatic S, Tricot G, Stone K, Zhan F, Moreno A, et al. Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma. J Immunother 2007;30:847-54. (Pubitemid 350295364)
20. Broyl A, Hose D, Lokhorst H, de Knegt Y, Peeters J, Jauch A, et al. Gene expression profiling for molecular classification ofmultiple myeloma in newly diagnosed patients. Blood 2010;116:2543-53.
21. R Development Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2008.
22. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004;5:R80.
23. Verzani. gWidgets: gWidgets API for building toolkit-independent, interactive GUIs [cited 2009 Sep 9]. Available from: http://cran.uvigo.es/web/ packages/gWidgets/gWidgets.pdf.
24. Kostka D, Spang R. Microarray based diagnosis profits from better documentation of gene expression signatures. PLoS Comput Biol 2008;4:e22.
25. Parman C, Halling C, Gentleman R. affyQCReport: QC Report generation for affyBatch objects [cited 2001 Apr 13]. Available from: http://bioconductor. wustl.edu/bioc/html/affyQCReport.html.
26. Bolstad B. Low level analysis of high-density oligonucleotide array data: background, normalization and summarization [dissertation]. Berkeley (CA): University of California; 2004.
27. Bolstad B, Collin F, Brettschneider J, Simpson K, Cope L, Irizarry R, et al. In: Gentleman R, Carey V, Huber W, Irizarry R, Dudoit S, editors. Quality assessment of Affymetrix GeneChip Data in bioinformatics and computational biology solutions Using R and Bioconductor. NewYork: Springer; 2005.
28. Brettschneider J, Collin F, Bolstad B, Speed TP. Quality assessment for short oligonucleotide microarray data. Technometrics 2008;50:279-83.
29. Wilson CL, Miller CJ. Simpleaffy: a BioConductor package for Affymetrix Quality Control and data analysis. Bioinformatics 2005;21:3683-5. (Pubitemid 41264111)
30. Warren P, Taylor D, Martini PGV, Jackson J, Bienkowska J. PANP - a new method of gene detection on oligonucleotide expression arrays [abstract]. In: Proceedings of the 7th IEEE International Conference; 2007 Oct 14-17; Boston, MA. Santa Clara (CA): IEEE; 2007. p. 108-15.
31. Tibshirani R, Hastie T, Narasimhan B, Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A 2002;99:6567-72. (Pubitemid 34526173)
32. Chng WJ, Glebov O, Bergsagel PL, Kuehl WM. Genetic events in the pathogenesis of multiple myeloma. Best Pract Res Clin Haematol 2007;20:571-96. (Pubitemid 350215376)
33. Leisch F. Sweave: dynamic generation of statistical reports using literate data analysis. In: Hárdle W, Rónz B, editors. Compstat 2002 - proceedings in computational statistics. Heidelberg, Germany: Physica Verlag; 2002. p. 575-80.
34. Rainer J. pgUtils: utility functions for PostgreSQL databases [cited 2011 Mar 22]. Available from: http://bioconductor.wustl.edu/bioc/html/pgUtils.html.
35. Rainer J. maDB: microarray database and utility functions for microarray data analysis [cited 2011 Mar 24]. Available from: http://bioconductor.wustl. edu/bioc/html/maDB.html.
36. Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK, et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009;23:2210-21.
37. Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 2007;109:3489-95. (Pubitemid 46572539)
38. Chiecchio L, Protheroe RK, Ibrahim AH, Cheung KL, Rudduck C, Dagrada GP, et al. Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma. Leukemia 2006;20:1610-7. (Pubitemid 44264105)
39. Keats JJ, Reiman T, Maxwell CA, Taylor BJ, Larratt LM, Mant MJ, et al. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood 2003;101:1520-9. (Pubitemid 36182529)
40. Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003;101:4569-75. (Pubitemid 36857829)
41. Moreau P, Facon T, Leleu X, Morineau N, Huyghe P, Harousseau J-L, et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood 2002;100:1579-83. (Pubitemid 34925131)
42. Chang H, Sloan S, Li D, Zhuang L, Yi Q-L, Chen CI, et al. The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. Br J Haematol 2004;125:64-8. (Pubitemid 38453279)
43. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906-17.
44. Avet Loiseau H, Moreau P, Mathiot C, Charbonnel C, Caillot D, Facon T, et al. Induction with Velcade(R)/dexamethasone partially overcomes the poor prognosis of t(4;14), but not that of Del(17p), in young patients with multiple myeloma. ASH Annu Meeting Abstr 2009;114:957.
45. Knop S, Gerecke C, Liebisch P, Topp MS, Platzbecker U, Sezer O, et al. Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). Blood 2009;113:4137-43.
46. Reece D, Song KW, Fu T, Roland B, Chang H, Horsman DE, et al. Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood 2009;114:522-5.
47. Boccadoro M, Gavarotti P, Fossati G, Pileri A, Marmont F, Neretto G, et al. Low plasma cell 3(H) thymidine incorporation in monoclonal gammopathy of undetermined significance (MGUS), smouldering myeloma and remission phase myeloma: a reliable indicator of patients not requiring therapy. Br J Haematol 1984;58:689-96. (Pubitemid 15176009)
48. Greipp PR, Katzmann JA, O'Fallon WM, Kyle RA. Value of beta 2-microglobulin level andplasmacell labelingindices as prognostic factors in patients with newly diagnosed myeloma. Blood 1988;72:219-23.
49. San Miguel JF, Garcia-Sanz R, Gonzalez M, Moro MJ, Hernandez JM, Ortega F, et al. A new staging system for multiple myeloma based on the number of S-phase plasma cells. Blood 1995;85:448-55.
50. Condomines M, Hose D, Rème T, Requirand G, Hundemer M, Schoenhals M, et al. Gene expression profiling and real-time PCR analyses identify novel potential cancer-testis antigens in multiple myeloma. J Immunol 2009;183:832-40.